584,048 Shares in Sanuwave Health Inc. $SNWV Purchased by Solas Capital Management LLC

Key Points

• Solas Capital Management LLC invested approximately $20.66 million in Sanuwave Health Inc., acquiring 584,048 shares, making it the institutional investor's second largest position.
• Shares of Sanuwave Health are currently rated as a "buy" by several analysts, with Roth Capital raising the price target from $54.00 to $55.00.
• Sanuwave Health reported $0.01 earnings per share for the last quarter, exceeding the consensus estimate of ($0.09), and had revenue of $10.16 million.

Solas Capital Management LLC bought a new position in Sanuwave Health Inc. (NASDAQ:SNWV - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 584,048 shares of the company's stock, valued at approximately $20,658,000. Sanuwave Health comprises 11.6% of Solas Capital Management LLC's portfolio, making the stock its 2nd largest holding. Solas Capital Management LLC owned about 6.83% of Sanuwave Health at the end of the most recent quarter.

Separately, Strategic Investment Solutions Inc. IL bought a new position in shares of Sanuwave Health during the 1st quarter worth $47,000. 42.53% of the stock is owned by hedge funds and other institutional investors.

Sanuwave Health Stock Performance

Shares of NASDAQ:SNWV traded down $0.38 during trading on Thursday, hitting $38.43. The company had a trading volume of 12,379 shares, compared to its average volume of 51,429. The stock has a fifty day moving average price of $37.20. Sanuwave Health Inc. has a one year low of $5.21 and a one year high of $46.58. The company has a market cap of $329.35 million, a PE ratio of -4.66 and a beta of 1.39.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.10. The business had revenue of $10.16 million during the quarter, compared to analysts' expectations of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Analyst Ratings Changes

SNWV has been the subject of several analyst reports. Roth Capital raised their target price on Sanuwave Health from $54.00 to $55.00 and gave the stock a "buy" rating in a research note on Friday, August 22nd. Wall Street Zen raised Sanuwave Health from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 30th. Northland Capmk upgraded Sanuwave Health to a "strong-buy" rating in a research report on Wednesday. Finally, Northland Securities started coverage on Sanuwave Health in a report on Wednesday. They issued an "outperform" rating and a $55.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $55.00.

Sanuwave Health Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.